• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

A new approach to Alzheimer’s disease trials

Research has established beyond doubt that Alzheimer’s dementia is a result of multiple disease processes. The hypothesis behind EPAD suggested that early, targeted intervention focused on the very first stages of disease will be more successful than efforts to tackle established disease processes have been. By delaying, preventing or eliminating the pathologies that begin in mid-life, it may be possible to block the cascade of events that, over subsequent decades, culminate in dementia symptoms.

This approach required greater insight into the life of the brain than has ever been achieved before. EPAD has been set up to find the answers.

Superior

The EPAD study design addressed the limitations of a traditional Phase II Alzheimer’s dementia trial, delivering a guaranteed trial-ready cohort of pre-screened participants and superior data at a faster rate than ever before.

Streamlined

EPAD aimed to efficiently deliver early, accurate results. Studying new drugs in a well-designed Phase II PoC trial with clinical endpoints prior to Phase III, and continuous evaluation against a shared placebo, EPAD utilised the power of adaptive design and Bayesian statistics to streamline trials, increase knowledge and improve outcomes.

Selective

Drug trials in Alzheimer’s research have to date been hampered by uncertainty in which population to test, and which outcome measures to use. EPAD provided one well-characterised cohort, with biomarker evidence of Alzheimer’s disease pathology and a consistent set of outcomes, so intervention owners can expect guaranteed recruitment, fewer screen failures and more accurate results.

Supported

The EPAD PoC was ready to use and provided all the major components required to run a clinical trial in Alzheimer’s disease. Interventions owners had to bring their intervention and we aimed to provide the comprehensive infrastructure to deliver the rest.

EPAD also provided supported access to global Alzheimer’s dementia experts and 39 partners ranging from world leading universities, major pharmaceutical companies, digital research organisations and CROs.

Flexible and efficient study design

The EPAD PoC study design provided comprehensive, ongoing assessment and analysis of interventions throughout the study lifecycle, allowing for a flexibility and efficiency not possible in traditional trial formats.

The study design incorporated:

  • Use of a cognitive measure as the primary endpoint.
  • Frequent evolutionary analyses for success and futility.
  • Advancement of compounds that achieve an effect on an intermediate phenotype or biomarker of target engagement to the clinical stage of the study (note: compounds that have already demonstrated target engagement may bypass this step).
  • Use of Bayesian statistical models to achieve faster randomisation to doses or interventions that appear more effective overall or in specific subpopulations.
  • Efficient use of the accruing data.
  • Randomisation to drug or placebo for each intervention, with analysis using combined data from all placebo subjects to increase the power of the analyses.

The PoC master protocol outlined our study design and requirements for all interventions.

Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Thanks Aridhia for your partnership to facilitate the latest and final @IMI_EPAD #data release. This contains the data for over 2000 participants of the EPAD Longitudinal Cohort Study. Researchers who are interested to access to this dataset can visit ep-ad.org/erap twitter.com/aridhia/status…

reply retweet favorite
1:25 pm · 2021-01-25
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.